Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk
出版年份 2022 全文链接
标题
Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk
作者
关键词
-
出版物
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-08-31
DOI
10.1007/s40618-022-01910-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine
- (2022) S. De Vincentis et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
- (2021) E. Söreskog et al. OSTEOPOROSIS INTERNATIONAL
- A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
- (2021) E. Söreskog et al. OSTEOPOROSIS INTERNATIONAL
- Osteoporosis care amidst the prolonged pandemic
- (2021) R. R. Narla et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
- (2021) H. Hagino et al. OSTEOPOROSIS INTERNATIONAL
- Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic?
- (2021) A. Falchetti et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis
- (2021) S. Nayak et al. OSTEOPOROSIS INTERNATIONAL
- Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older
- (2020) Emma Söreskog et al. BONE
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS—2020 UPDATE
- (2020) Pauline M. Camacho et al. Endocrine Practice
- Predictors of imminent risk of fracture in Medicare-enrolled men and women
- (2020) Akeem A. Yusuf et al. Archives of Osteoporosis
- An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
- (2020) Nannan Li et al. PHARMACOECONOMICS
- Cost-Effectiveness of Sequential Treatment with Abaloparatide vs. Teriparatide for United States Women at Increased Risk of Fracture
- (2019) Mickael Hiligsmann et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
- (2019) Patricia Barrionuevo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Predictors of imminent non-vertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos)
- (2019) Jonathan D. Adachi et al. Archives of Osteoporosis
- Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
- (2019) Alison Stopeck et al. JOURNAL OF MEDICAL ECONOMICS
- ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
- (2018) Henry G Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
- (2018) Quang A. Le et al. ANNALS OF PHARMACOTHERAPY
- Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation
- (2018) M. Hiligsmann et al. OSTEOPOROSIS INTERNATIONAL
- Risk of subsequent fracture after prior fracture among older women
- (2018) A. Balasubramanian et al. OSTEOPOROSIS INTERNATIONAL
- The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures
- (2017) Dennis M Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in osteoporosis and low bone mass in older US adults, 2005–2006 through 2013–2014
- (2017) A. C. Looker et al. OSTEOPOROSIS INTERNATIONAL
- Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States
- (2017) Emily Durden et al. Archives of Osteoporosis
- A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures
- (2016) Sarah Davis et al. HEALTH TECHNOLOGY ASSESSMENT
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
- (2016) Paul D. Miller et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA
- (2016) T. Mori et al. OSTEOPOROSIS INTERNATIONAL
- Imminent risk of fracture after fracture
- (2016) H. Johansson et al. OSTEOPOROSIS INTERNATIONAL
- Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men
- (2013) Patrick Haentjens ANNALS OF INTERNAL MEDICINE
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. VALUE IN HEALTH
- Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
- (2013) Anju Parthan et al. Applied Health Economics and Health Policy
- Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis
- (2012) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
- (2010) I. R. Reid et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
- (2010) B. Jönsson et al. OSTEOPOROSIS INTERNATIONAL
- Health Care Expenditures Associated With Skeletal Fractures Among Medicare Beneficiaries, 1999–2005
- (2009) Meredith L Kilgore et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Updated fracture incidence rates for the US version of FRAX®
- (2009) B. Ettinger et al. OSTEOPOROSIS INTERNATIONAL
- Clinical subsequent fractures cluster in time after first fractures
- (2008) T A C M van Geel et al. ANNALS OF THE RHEUMATIC DISEASES
- Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature
- (2008) Mickaël Hiligsmann et al. CALCIFIED TISSUE INTERNATIONAL
- Medication Compliance and Persistence: Terminology and Definitions
- (2007) Joyce A. Cramer et al. VALUE IN HEALTH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started